EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Hepatitis C Eradication Improves Oncologic and Clinical Outcomes in Patients Treated With Atezolizumab Plus Bevacizumab

Leonardo Stella iD, Giuseppe Cabibbo, Ciro Celsa, Roberta Ciccia, Alba Sparacino, Fabio Piscaglia, Francesco Tovoli, Andrea Arleo, Bernardo Stefanini iD, Massimo Iavarone, Roberta D'Ambrosio, Lucia Cerrito und 19 weitere

Liver International · 2025

DOI: 10.1111/liv.70362 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Liver International, 2025. Verfasst von Leonardo Stella und 30 weiteren Autor:innen. Beteiligte Einrichtung: Liver Unit, CEMAD Centro Malattie del'Apparato Digerente, Medicina Interna e Gastroenterologia, Fondazione Policlinico Universitario Gemelli IRCCS, R…. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Bevacizumab, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Hepatitis C virus (HCV) is a key driver of hepatocellular carcinoma (HCC). However, the impact of HCV eradication on systemic therapy remains unclear. We aimed to assess the safety and efficacy of direct‐acting antivirals (DAA) in patients treated with Atezolizumab plus Bevacizumab (AtezoBev).

Methods

This retrospective multicentre study included patients with HCV‐related unresectable/advanced HCC treated with AtezoBev between 2021 and 2024. Three groups of patients were compared: Group A ( n = 22), concurrent DAA with AtezoBev; Group B ( n = 95), antiviral therapy before AtezoBev; and Group C ( n = 22), active infection.

Results

Group A showed the longest median overall survival (42.8 months) compared to Group B (26.8 months; p = 0.03) and Group C (19.7 months; p = 0.01). Time to progression and progression‐free survival were significantly prolonged in Group A versus Groups B and C. Moreover, Group A exhibited a higher disease control rate than the other groups. Post‐DAA decompensation rates were significantly lower in Group A (4.5%) compared to Groups B (26.3%) and C (36.4%). Treatment‐related adverse events of grade ≥ 3 were similar across groups. In the multivariate competing risk analysis with adjustment for time‐dependent variables, achieving sustained virologic response during AtezoBev showed a protective effect against liver decompensation (sHR 0.02, p = 0.003) or tumour progression (sHR 0.14, p = 0.009), and was also associated with reduced mortality (HR 0.29, p = 0.005).

Conclusions

Achieving a SVR during AtezoBev seems to improve oncologic outcomes and reduce liver decompensation in patients with unresectable/advanced HCC. An integrated therapeutic approach can optimise systemic treatment efficacy, particularly in patients eligible for conversion strategies. Trial Registration Protocol ID: 5890

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsCarcinoma, HepatocellularBevacizumabAntibodies, Monoclonal, HumanizedAntiviral AgentsAntineoplastic Combined Chemotherapy ProtocolsHepatitis CHumansMaleFemaleRetrospective StudiesMiddle AgedAgedTreatment OutcomeDrug Therapy, CombinationProgression-Free SurvivalHepacivirus

Stichwörter der Autor:innen

DAAHCVcirrhosishepatocellular carcinomaimmunotherapyliver decompensationsurvival

Substanzen

atezolizumabBevacizumabAntibodies, Monoclonal, HumanizedAntiviral Agents

Autor:innen und Institutionen

  • Liver Unit, CEMAD Centro Malattie del'Apparato Digerente, Medicina Interna e Gastroenterologia, Fondazione Policlinico Universitario Gemelli IRCCS, Rome, Italy.
  • Policlinico Universitario «Paolo Giaccone», Azienda Ospedaliera Universitaria, Palermo, Italy.
  • Department of Surgery and Cancer, Imperial College London, London, UK.
  • Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
  • Gastroenterology and Hepatology Department, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.

ORCID-Profile: Leonardo Stella, Bernardo Stefanini, Fabio Marra, Alessio Aghemo, Francesca Romana Ponziani

Zitieren

APA

Stella, L., Cabibbo, G., Celsa, C., Ciccia, R., Sparacino, A., Piscaglia, F., Tovoli, F., Arleo, A., Stefanini, B., Iavarone, M., D'Ambrosio, R., Cerrito, L., Pallozzi, M., Santopaolo, F., Marra, F., Campani, C., Mazzarelli, C., Viganò, R., Tortora, R., …, & Ponziani, F. R. (2025). Hepatitis C Eradication Improves Oncologic and Clinical Outcomes in Patients Treated With Atezolizumab Plus Bevacizumab. Liver International. https://doi.org/10.1111/liv.70362

Vancouver

Stella L, Cabibbo G, Celsa C, Ciccia R, Sparacino A, Piscaglia F, et al. Hepatitis C Eradication Improves Oncologic and Clinical Outcomes in Patients Treated With Atezolizumab Plus Bevacizumab. Liver International. 2025. doi:10.1111/liv.70362

BibTeX
@article{Stella2025,
  author = {Stella, Leonardo and Cabibbo, Giuseppe and Celsa, Ciro and Ciccia, Roberta and Sparacino, Alba and Piscaglia, Fabio and Tovoli, Francesco and Arleo, Andrea and Stefanini, Bernardo and Iavarone, Massimo and D'Ambrosio, Roberta and Cerrito, Lucia and Pallozzi, Maria and Santopaolo, Francesco and Marra, Fabio and Campani, Claudia and Mazzarelli, Chiara and Viganò, Raffaella and Tortora, Raffaella and Aghemo, Alessio and Nicola, Stella De and Pressiani, Tiziana and Rimassa, Lorenza and Bhoori, Sherrie and Corallo, Salvatore and Maiocchi, Laura and Martini, Andrea and Soldà, Caterina and Russo, Francesco Paolo and Gasbarrini, Antonio and Ponziani, Francesca Romana},
  title = {Hepatitis C Eradication Improves Oncologic and Clinical Outcomes in Patients Treated With Atezolizumab Plus Bevacizumab},
  journal = {Liver International},
  year = {2025},
  doi = {10.1111/liv.70362}
}
Kostenlos starten →